Kevin (Penghui) Chen
Founder & Partner @ BioTrack Capital
Kevin (Penghui) Chen is a seed investor at BioTrack Capital focused on Health Care and Biotechnology. Kevin (Penghui) Chen is the Founder & Partner of BioTrack Capital.He attend to the Kellogg School of Management in 2001.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Kevin (Penghui) Chen invests in
Stages Kevin (Penghui) Chen invests in
Countries Kevin (Penghui) Chen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (57%)
- Biotechnology 2 (29%)
- Manufacturing 2 (29%)
- Medical 1 (14%)
- Robotics 1 (14%)
Stage
- Seed 2 (29%)
- Angel 1 (14%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
Country
- China 5 (71%)
- United States 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $35M / Seed / Jan 30, 2026 | |
|
Microlon Biotechnology
|
Microlon Biotechnology is an innovative high-tech company that specializes in microfluidic intelligent manufacturing technologies. | Seed / Nov 21, 2025 | |
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $27.8M / Angel / Jun 04, 2025 | |
| Yizhun Intelligent is an AI & Robotics company. | Series C / Jun 21, 2021 | ||
| SeekGene is a provider of genetic data analysis solutions focused on the development and clinical transformation of single cell sorting assays. The SeekGene operations team has many years of research and clinical service experience, focusing on the application of single-cell sequencing technology in real-world clinical research. Its self-developedhigh-throughput single-cell transcriptome sequencing kit achieves world-leading performance, and is flexible, simple, economical, and accurate, which can accelerate the clinical transformation of single-cell sequencing technology. | $15.4M / Series A / Jan 08, 2021 | ||
| Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development. | Series B / Aug 03, 2020 | ||
| CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effectivemanagement care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing. | $50.9M / Series F / Jul 01, 2020 |
Co-Investors
About BioTrack Capital
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
BioTrack Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Feng Tao
Co-Founder & Partner
|
|||
Jiacong Guo
Executive Director
|
|||
|
Kevin (Penghui) Chen
Founder & Partner
|
|||
|
Zhang Ye
Project Manager
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kevin (Penghui) Chen invest in?
Kevin (Penghui) Chen invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Seed and Angel stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kevin (Penghui) Chen?
Public channels for Kevin (Penghui) Chen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kevin (Penghui) Chen last invest?
The most recent investment recorded for Kevin (Penghui) Chen closed in Jan 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
